First clinical case of KPC-3-producing Klebsiella michiganensis in Europe

S N Seiffert; D Wüthrich; Y Gerth; A Egli; P Kohler; O Nolte

doi:10.1016/j.nmni.2019.100516

First clinical case of KPC-3-producing Klebsiella michiganensis in Europe

New Microbes New Infect. 2019 Feb 23:29:100516. doi: 10.1016/j.nmni.2019.100516. eCollection 2019 May.

Authors

S N Seiffert¹, D Wüthrich^{2

3

4}, Y Gerth¹, A Egli^{2

3}, P Kohler⁵, O Nolte¹

Affiliations

¹ Division of Human Microbiology, Centre for Laboratory Medicine, Switzerland.
² Division of Clinical Microbiology, Switzerland.
³ Applied Microbiology Research Unit, Department of Biomedicine, University of Basel, Switzerland.
⁴ Swiss Institute of Bioinformatics, Basel, Switzerland.
⁵ Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St Gall, St Gall, Switzerland.

Abstract

Klebsiella michiganensis is a newly emerging human pathogen. We describe a case of bloodstream infection in an immunocompromised patient. The pathogen was repeatedly isolated from blood and one rectal swab, and was identified using routine standard procedures. Further investigations revealed that the K. michiganensis was multidrug resistant, carrying a plasmid harbouring a Klebsiella pneumoniae carbapenemase (KPC)-3 carbapenemase gene. This plasmid has been frequently encountered in K. pneumoniae isolates in Europe but has never been described in K. michiganensis.

Keywords: Antibiotic resistance; Enterobacterales; KPC; carbapenemase; ceftazidim/avibactam.